The recently published followup of the famous PREDIMED randomized controlled trial is some of the strongest evidence ever published for a possible protective effect of alcohol against CVD. (Emphasis on the word “possible”, because this is not proven and has become a topic of active debate in cardiology.)
The groups were initially randomized to a traditional Mediterranean diet including red wine vs. an AHA style diet without wine. The researchers tracked wine consumption in a subset of both groups with a urinary biomarker that is unique to wine (tartaric acid). This is the most accurate way of tracking alcohol consumption ever used in a long term study to date.
People with urinary levels of tartaric acid reflecting mild-to-moderate wine consumption in the 9 year followup to the trial had significantly lower rates of heart attack, stroke, heart failure, as well as overall cardiovascular mortality.
The hazard ratio for mild-to-moderate wine consumption— as compared to no wine consumption— was 0.5, meaning a 50% relative risk reduction. This is a very large effect, as far as CVD studies go.
The magnitude of this risk reduction is consistent with the 25%-40% risk reduction that has been seen in aggregate in over 100 prospective observational studies:
↪ Harvard: 100+ cohorts show 25-40% lower CVD risk with light-to-moderate alcohol
Quoted:
The implications of this study are far-reaching, particularly in the context of nutritional epidemiology and public health recommendations," wrote Giovanni de Gaetano, MD, PhD, of IRCCS NEUROMED in Pozzilli, Italy, and colleagues in an accompanying editorial.
"The use of an objective biomarker such as urinary tartaric acid represents a significant methodological advancement in alcohol research. It offers a more accurate and reliable measure of wine consumption, which could help resolve some of the ongoing debates about the health effects of alcohol,” they added. "Humans, for various reasons, are often not truthful and tend to either deny or under-report their alcohol intake."
"Moreover, the findings suggest that wine consumption in real-life conditions, unaffected by the often artificial influences of a clinical trial setting, might have a more beneficial impact on cardiovascular health than previously thought," they noted.
Note that we are finally getting a large long-running randomized controlled that directly tests alcohol (red wine) verses cardiovascular disease.
The study will run for 5 years, and also report on secondary endpoints of cancer and all-cause mortality:
↪ New 5-year RCT from the PREDIMED lead investigator will test red wine versus CVD
And it will be run in the same style as the famous PREDIMED trial that tested a Mediterranean diet vs CVD. In fact, it will be run by the same principle investigator as PREDIMED.
It will finally give us the truth on mild-to-moderate alcohol consumption and health, whatever that may be.